Exon expression arrays as a tool to identify new cancer genes

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Schutte, Mieke ^a   Elstrodt, Fons ^a   Bralten, Linda B C ^a   Nagel, Jord H A ^a   Duijm, Elza ^a   Hollestelle, Antoinette ^a   Vuerhard, Maartje J ^a   Wasielewski, Marijke ^a   Peeters, Justine K ^a   van der Spek, Peter ^a   Sillevis Smitt, Peter A ^a   French, Pim J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RETINOBLASTOMA PROTEIN; UVOMORULIN;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CONTROLLED STUDY; DNA MICROARRAY; EXON; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATTERN BASED CORRELATION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; WILD TYPE; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; POPULATION GENETICS; TUMOR CELL LINE; TUMOR GENE;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EXONS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GENETICS, POPULATION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PTEN PHOSPHOHYDROLASE; TRANSCRIPTION, GENETIC;

EID: 51749083446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003007     Document Type: Article

References (24)

1. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353.
2. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
3. Samuels Y, Wang Z, Bardelli A, Silliman N, PtakJ, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
4. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
5. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, et al. (2004) Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36: 979-983.
6. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
7. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, et al. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54: 3845-3852.
8. Frederick L, Eley G, Wang XY, James CD (2000) Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro-oncol 2: 159-163.
9. Faustino NA, Cooper TA (2003) Pre-mRNA splicing and human disease. Genes Dev 17: 419-437.
10. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
11. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
12. Blencowe BJ (2006) Alternative splicing: new insights from global analyses. Cell 126: 37-47.
13. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, et al. (2007) Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 67: 5635-5642.
14. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, et al. (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66: 41-45.
15. van de Wetering M, Barker N, Harkes IC, van der Heyden M, Dijk NJ, et al. (2001) Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res 61: 278-284.
16. Su GH, Song JJ, Repasky EA, Schutte M, Kern SE (2002) Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat 19: 81.
17. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M (2007) Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines. Mol Cancer Res 5: 195-201.
18. Wasielewski M, Elstrodt F, Klijn JG, Berns EM, Schutte M (2006) Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res Treat 99: 97-101.
19. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60: 1383-1387.
20. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, et al. (2004) Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 21: 53-56.
21. Mischel PS, Cloughesy TF, Nelson SF (2004) DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5: 782-792.
22. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, et al. (2007) Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 8: R64.
23. French PJ, Swagemakers SMA, Nagel JHA, Kouwenhoven MCM, Brouwer E, et al. (2005) Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 65: 11335-11344.
24. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.